Assesment of changes of coagulatory/ fibrinolysis factors after major hepatectomy or pancreatoduodenectomy
Not Applicable
- Conditions
- Biliary tract carcinoma Hepatocellular carcinoma Pancreas cancer
- Registration Number
- JPRN-UMIN000006642
- Lead Sponsor
- agoya university Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who reject to be enrolled in this study Patients who do not fulfill the criteria of this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FDP D dimer fibrinogen PT APTT platelet PIC TAT ADAMTS13 factor7 factor13 VWF
- Secondary Outcome Measures
Name Time Method intra-operative bleeding volume of transfusion operation time blood examination
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link coagulatory/fibrinolysis factor changes to post-hepatectomy outcomes in hepatocellular carcinoma patients?
How do coagulation profiles after pancreatoduodenectomy compare to standard-of-care monitoring in pancreatic cancer surgery?
Which biomarkers (e.g., D-dimer, PAI-1) predict hypercoagulability risk in biliary tract carcinoma patients undergoing major hepatectomy?
What adverse events correlate with fibrinolysis factor alterations in JPRN-UMIN000006642's hepatocellular carcinoma cohort?
How do anticoagulant therapies like DOACs interact with post-surgical coagulation dynamics in pancreas cancer patients from this trial?